Valuation: PharmaTher Holdings Ltd.

Market Cap 3.64M 2.54M 2.32M 2.13M 1.94M 235M 3.83M 25.97M 10.32M 129M 9.54M 9.34M 404M P/E 2025
-12.2x
P/E 2026 -9.69x
Enterprise Value 2.72M 1.9M 1.73M 1.59M 1.45M 176M 2.86M 19.39M 7.71M 96.03M 7.12M 6.97M 301M EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
81.26%
Yield 2025 *
-
Yield 2026 -
10-29 PharmaTher Holdings Ltd. Reports Earnings Results for the First Quarter Ended August 31, 2026 CI
10-29 Pharmather Builds Portfolio of Personalized, 3D-Printed Peptide Products for New U.S. Peptide Pathway, Led by Colon-Targeted Kpv and Bpc-157 CI
10-28 Pharmather Holdings Ltd. Submits Applications to Fda for 3D-Printed Creatine Monohydrate in Gamt Deficiency CI
10-07 PharmaTher Holdings Ltd. Launches M3DICINES? National Network Program To Provide 3D-Printed Medicines CI
10-01 PharmaTher Holdings Ltd. and Craft Health Pte. Ltd. Enter Into Exclusive North American Distribution Agreement For CraftMake? Pharmaceutical 3D Printing Platform CI
09-28 PharmaTher Holdings Ltd. Reports Earnings Results for the Full Year Ended May 31, 2026 CI
09-27 PharmaTher Holdings Ltd. Auditor Raises 'Going Concern' Doubt CI
08-11 PharmaTher Holdings Ltd. Establishes PERSONALIZ3D To Commercialize A Personalized Medicine Platform Combining Telehealth And Pharmaceutical 3D Printing CI
07-29 PharmaTher Holdings Ltd. Collaborates With Craft Health Pte. Ltd. To Evaluate CraftMake GMP-Ready Pharmaceutical 3D Printing Platform For Personalized Peptides CI
07-27 PharmaTher Launches New Division to Commercialize Personalized Peptide Products MT
07-27 Pharmather Establishes Personaliz3d Peptides Division to Address Personalized Peptide Care CI
07-21 PharmaTher Holdings Ltd Announces Collaboration To Advance KetaMist Needle-Free Ketamine Treatment Toward FDA Approval CI
07-15 PharmaTher Holdings Updates Strategy On Personalized Medicines For Peptides And Psychedelics CI
1 day-11.11%
1 week-20.00%
Current month-27.27%
1 month-27.27%
3 months-27.27%
6 months-38.46%
Current year-61.90%
1 week 0.04
Extreme 0.04
0.06
1 month 0.04
Extreme 0.04
0.06
Current year 0.04
Extreme 0.04
0.12
1 year 0.04
Extreme 0.04
0.14
3 years 0.04
Extreme 0.04
0.77
5 years 0.04
Extreme 0.04
0.77
10 years 0.04
Extreme 0.04
1.24
Manager TitleAgeSince
Chief Executive Officer - 2019-12-31
Director of Finance/CFO 55 2020-05-31
Director TitleAgeSince
Chairman - 2019-12-31
Director/Board Member - 2020-05-31
Director/Board Member - 2020-05-31
Date Insider Type Main position Quantity % Market Cap. Importance
4/17/26 Buy

Chief Financial Officer

400,000 0.4395%
4/17/26 Other

Chief Financial Officer

400,000 0.4395%
4/17/26 Other

Chief Financial Officer

400,000 0.4395%
Change 5-day change 1-year change 3-year change Capi.($)
-11.11%-20.00%-71.43%-65.22% 2.86M
-0.30%-5.62%+28.35%+127.66% 1,204B
+1.25%-4.60%+33.56%+80.57% 643B
+0.94%-2.80%+22.88%+106.94% 501B
-0.60%-2.39%+27.92%+67.00% 378B
+0.69%-9.00%+40.68%+31.42% 327B
+0.41%-4.81%+24.99%+51.91% 285B
+0.81%-3.72%-1.35%+30.72% 270B
-0.15%-6.73%+27.23%+64.15% 237B
-0.06%-0.91%+29.95%+120.58% 207B
Average -0.78%-3.96%+16.28%+61.57% 405B
Weighted average by Cap. +0.39%-4.71%+27.25%+88.32%

Financials

2025 2026
Net sales - -
Net income -1.53M -1.07M -971K -894K -813K -98.67M -1.6M -10.88M -4.33M -53.89M -4M -3.91M -169M -610K -426K -388K -358K -325K -39.47M -642K -4.35M -1.73M -21.56M -1.6M -1.57M -67.66M
Net Debt -1.12M -784K -714K -658K -599K -72.62M -1.18M -8.01M -3.18M -39.67M -2.94M -2.88M -124M -922K -643K -586K -540K -491K -59.58M -969K -6.57M -2.61M -32.54M -2.41M -2.36M -102M
Projected Income Statement - Annual - PharmaTher Holdings Ltd.
Logo PharmaTher Holdings Ltd.
PharmaTher Holdings Ltd. is a Canada-based specialty pharmaceutical company. The Company develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The Company is also commercializing PharmaPatch (microneedle patch) with its partners to deliver psychedelics and drugs to treat infectious diseases. The Company is in the development of programs for the delivery of KETARX (ketamine) in a patch and on-body pump for mental health, pain and medical countermeasures indications.
Employees
-
Date Price Change Volume
26-11-20 $0.0400 -11.11% 18,850
26-11-19 $0.0450 0.00% 104,667
26-11-18 $0.0450 0.00% 4,000
26-11-17 $0.0450 -10.00% 36,763
26-11-16 $0.0500 0.00% 30,000
  1. Stock Market
  2. Stocks
  3. PHRM Stock